Japan approves GSK’s Sotrovimab COVID-19 antibody treatment

Popular Categories

Subscribe Here

imageStock Markets10 minutes ago (Sep 27, 2021 08:17AM ET)

2/2
(C) Reuters. FILE PHOTO: A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

2/2

TOKYO (Reuters) – Japan has approved GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.

The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.

Japan approves GSK’s Sotrovimab COVID-19 antibody treatment

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Explore

Up Next

Discover

Other Articles